Ipamorelin research at Peptide Pros USA
A selective GHRP has a compelling description. Its human studies give that description some awkward company.
Human GH measurements
The human pharmacokinetic study recorded a single discrete GH pulse, peaking about 40 minutes after intravenous administration, with an ipamorelin terminal half-life of approximately 2 hours. It studied healthy male volunteers, with eight per dose level. I respect the precision of that small experiment: it describes the signal the peptide produces.
Ipamorelin and HGH act at different points. Ipamorelin stimulates the body’s GH release through GHS-R1a, the receptor activated by ghrelin; it supplies no HGH itself. This ipamorelin research peptide is a synthetic pentapeptide, a chain of five amino acids, derived from GHRP-1. The secretagogue review discusses the pharmacological class.
Does ipamorelin increase cortisol?
Ipamorelin’s selective GHRP reputation comes from preclinical pharmacology in rats and swine: it released GH without meaningfully increasing ACTH, cortisol or prolactin, even at exposure well above that needed for GH release. The class review provides context for the selective secretagogue mechanism. That is the specific advantage being claimed.
My caution starts when selectivity stands in for a complete safety record. It concerns particular hormone responses in particular experiments. Human evidence on chronic exposure remains narrow, and the same receptor family also reaches appetite and metabolic pathways.
Postoperative ileus
The 2014 randomized trial in 114 bowel-resection patients tested postoperative ileus. Median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo (P=0.15); the primary endpoint was not met. I would have welcomed a clear practical gain here. The study did not establish one.
Treatment-emergent adverse events occurred in 87.5% of the ipamorelin arm and 94.8% of the placebo arm, with no ipamorelin-specific safety signal in that short perioperative window. Those high rates come from a surgical population. They give no dependable estimate for long-term use by healthy adults.
Weight preservation and rat bones
In the 2024 ferret experiment involving cisplatin, ipamorelin inhibited body-weight loss by approximately 24% on the last day of the delayed phase (48–72 hours), while showing no anti-emetic effect. It was an animal chemotherapy model. Preserving weight there says something quite different from a human fat-loss claim.
The bone-growth experiment in adult female rats found increased longitudinal growth without a measurable change in total IGF-1, IGF-binding proteins or bone turnover markers. That awkward outcome appeals to me: it discourages a tidy account in which every tissue effect can be read from the blood IGF-1 value. It remains a rat finding.
Safety and the American status
A 28-day rat study of GSK894281 found heart-muscle degeneration and necrosis. GSK894281 was a different ghrelin-receptor agonist; ipamorelin was not tested in that experiment. This is a receptor-class warning signal, with ipamorelin’s long-term cardiovascular safety still uncharacterized.
Community accounts of better sleep and recovery sit beside accounts of flushing, hunger, puffiness, local irritation and tingling. They are anecdotal reports rather than clinical evidence, and neither benefit nor harm can be assigned a reliable frequency from them. The class safety review also flags blood-glucose and insulin-sensitivity concerns.
Ipamorelin has never been FDA-approved. On FDA’s page current as of April 22, 2026, ipamorelin acetate remains Category 2 for 503B outsourcing facilities and also appears in the withdrawn-nomination table for 503A. Its safety concerns persist. Withdrawal of a nomination provides neither permission to compound nor a move into Category 1. Ipamorelin is prohibited in sport under WADA S2. The combination page examines the additional uncertainty when it is paired with CJC-1295.